Shanghai Rongtai Health Technology Corporation (603579) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 3.9B CNY
Fair value as of: Jul 11, 2026
From 24 valuation models · updated 30 days ago
Share price +2.2% over the past month.
Below-average quality, and screening another 49% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥11.22). The favourable scenario is already priced in.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range ¥11.36 – ¥43.26 · fair‑value band ¥7.04 – ¥11.22 · the ¥18.35 price screens above the ¥9.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Shanghai Rongtai Health Technology Corporation (603579) currently trades at ¥18.35, while our model-based Fair Value estimate is ¥9.39, implying the stock looks roughly 48.8% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai Rongtai Health Technology Corporation generated revenue of 1.6B CNY at a net margin of 10.9%. Revenue grew 12.0% year over year. It earns a return on equity of 7.1%. Net debt stands at 575M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥7.04 (bear case) to ¥11.22 (bull case); at ¥18.35, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 59% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at 2% fair-value upside, at -49%, 603579 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (¥12.80) versus Dividend Discount (¥3.75). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Rongtai Health Technology Corporation Limited, together with its subsidiaries, engages in the research, design, development, production, and sale of massage equipment under the Rongtai and Momoda brands in China and internationally.
Full company description
Shanghai Rongtai Health Technology Corporation Limited, together with its subsidiaries, engages in the research, design, development, production, and sale of massage equipment under the Rongtai and Momoda brands in China and internationally. The company offers massage chairs and accessories, neck massagers, eye massagers, massage backrests, massage belts, foot massagers, massage pads, and handheld massagers, etc.; ankle revive, ROVO walking, small massagers, and other products; and smart home health gadgets, including slimming machines and beauty devices. It also provides shared massage services, as well as purchase and after-sale services. The company sells its products through direct sales, e-commerce, sales counters in department stores, and distributors. It exports its products. The company is also involved in the software and financial; import and export of goods and technologies; technology promotion and application; investing; and wholesale and retail trade activities. Shanghai Rongtai Health Technology Corporation Limited was founded in 1997 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Rongtai Health Technology Corporation reported revenue of ¥1.6B in FY2025 versus ¥2.6B in FY2021, a compound −11.9%/yr. Reported net income was ¥151M in FY2025, compounding −10.6%/yr from FY2021.
603579 screens 49% overvalued. Compare with ANTA Sports Products Limited →
Peer Group
Leisure · 192 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Leisure median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Leisure stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ANTA Sports Products Limited 2020 | HK$74.15 | HK$119.29 | +61% |
| Pop Mart International Group 9992 | HK$160.20 | HK$227.30 | +42% |
| Amer Sports, Inc AS | $36.44 | $16.16 | -56% |
| Hasbro, Inc HAS | $81.55 | $83.38 | +2% |
| Life Time Group LTH | $42.15 | $16.15 | -62% |
| Acushnet Holdings GOLF | $114.78 | $37.79 | -67% |
| Li Ning Company 2331 | HK$14.80 | HK$29.26 | +98% |
| Benefit Systems S.A BFT | 5,255 PLN | 3,714 PLN | -29% |
| Ninebot Limited 689009 | ¥37.82 | ¥39.17 | +4% |
| Asmodee Group ASMDEEB | kr 145.70 | kr 41.90 | -71% |
Compare Shanghai Rongtai Health Technology Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Shanghai Rongtai Health Technology Corporation (603579) overvalued or undervalued?
What is the fair value of 603579?
What is the quality score of 603579?
What is the revenue of Shanghai Rongtai Health Technology Corporation (603579)?
What is the net profit margin of 603579?
Does Shanghai Rongtai Health Technology Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Rongtai Health Technology Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.